Prostate Cancer

Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

lan M. Thompson Jr, MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.

Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.

The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.

Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.

The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.

The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.

Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Brian Myre, MD, discusses early data with SYNC-T SV-102 in advanced/metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses data from subgroup analyses of the PSMAddition trial by disease volume and in de novo/recurrent mHSPC.

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.